

ZELTIA NEWS:

GENOMICA AB starts its commercial activity

Madrid, 22nd January 2013: GENOMICA SAU climbs another step in its successful internationalization process by establishing, as the date of January 17th 2013, its Scandinavian subsidiary, GENOMICA AB.

Based in Lund (Sweden), AB GENOMICA intends to support the Scandinavian market (Denmark, Sweden and Norway), due to its strategic importance and also for its high growth potential.

GENOMICA began its international expansion in 2006, focusing initially on the European market. Already in 2007, leap to America, expanding its market to countries in Central and South America. Today, only 5 years later GENOMICA is present in more than 35 countries worldwide and is actively continuing its global expansion.

About Zeltia

Zeltia S.A. is a world-leading biopharmaceutical company specialised in the development of marine-based drugs for use in oncology and central nervous system illnesses. Grupo Zeltia consists mainly of the following companies: PharmaMar, the world-leading biotechnology company in advancing cancer care through the discovery and development of innovative marine-derived medicines; Genómica, Spain's leading molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi); and a chemical division comprising Zelnova and Xylazel, two highly profitable companies that are leaders in their respective market segments.

About GENOMICA

GENOMICA S.A.U. is Spain's leading molecular diagnostics company. Founded in 1990, the company is based in the Madrid region. It is wholly owned by Zeltia. The company's mission is to apply quality and automation to improve the current approach to molecular diagnostics in the life sciences. The company's main goal is to lead the Spanish market in genomic applications and expand internationally in the area of molecular diagnostics and personalised medicine by designing, developing and selling new diagnostic applications based on the CLART® (CLINICAL ARRAY TECHNOLOGY) platform. GENOMICA has developed a diagnostic test for human papilloma virus (associated with cervical cancer), a system for diagnosing respiratory viruses, and a method for detecting human herpes virus; it also markets a test for detecting genetic markers associated with response to therapy. GENOMICA is a leading supplier of genetic identification services in legal and forensic medicine and in technology transfer (turnkey laboratories). <http://www.genomica.es/>



For more information, contact Zeltia at +34 91 444 4500.

This note is also available in the "News" section of the Zeltia (www.zeltia.com) and GENOMICA (www.genomica.es) websites